Editorial & Opinion
Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy.
| العنوان: | Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. |
|---|---|
| المؤلفون: | Chakraborty R; Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA., Rybicki L; Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Valent J; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Garcia AVM; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Faiman BM; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Khouri J; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Samaras CJ; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Anwer F; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Khorana AA; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. khorana@ccf.org. |
| المصدر: | Blood cancer journal [Blood Cancer J] 2021 Jun 25; Vol. 11 (6), pp. 121. Date of Electronic Publication: 2021 Jun 25. |
| نوع المنشور: | Letter |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, NY : Nature Pub. Group |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Multiple Myeloma*/drug therapy , Multiple Myeloma*/mortality , Thromboembolism*/chemically induced , Thromboembolism*/mortality , Thromboembolism*/prevention & control, Aspirin/*administration & dosage , Heparin, Low-Molecular-Weight/*administration & dosage , Warfarin/*administration & dosage, Adult ; Aged ; Aged, 80 and over ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate |
| References: | Lancet Oncol. 2009 Oct;10(10):943-9. (PMID: 19726226) Blood. 2010 Jun 17;115(24):4991-8. (PMID: 20299513) Blood. 2020 Aug 27;136(9):1091-1104. (PMID: 32438407) TH Open. 2020 May 23;4(2):e107-e112. (PMID: 32462111) Blood. 2010 Jul 8;116(1):22-6. (PMID: 20339094) Haematologica. 2012 Oct;97(10):1603-7. (PMID: 22511493) Expert Rev Anticancer Ther. 2017 Jul;17(7):585-591. (PMID: 28508703) J Am Coll Cardiol. 2017 Aug 22;70(8):926-938. (PMID: 28818202) Nat Commun. 2020 Jun 12;11(1):2996. (PMID: 32533060) Toxicol Sci. 2011 Nov;124(1):215-24. (PMID: 21865289) N Engl J Med. 2017 Jul 13;377(2):111-121. (PMID: 28636844) Leukemia. 2008 Feb;22(2):414-23. (PMID: 18094721) |
| المشرفين على المادة: | 0 (Heparin, Low-Molecular-Weight) 5Q7ZVV76EI (Warfarin) 69G8BD63PP (Bortezomib) 7S5I7G3JQL (Dexamethasone) 8N3DW7272P (Cyclophosphamide) R16CO5Y76E (Aspirin) |
| تواريخ الأحداث: | Date Created: 20210626 Date Completed: 20220131 Latest Revision: 20220131 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8233391 |
| DOI: | 10.1038/s41408-021-00513-4 |
| PMID: | 34172719 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2044-5385 |
|---|---|
| DOI: | 10.1038/s41408-021-00513-4 |